Systemic cancer therapy: evolution over the last 60 years.

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• The 1940s initiated key cancer chemotherapy concepts like the log kill hypothesis.
• Early successes with nitrogen mustards and antifolates spurred drug discovery, yielding predominantly genotoxic agents.
• The 21st century ushered in a new era, leveraging insights into tumor microenvironment and targeted therapy.

Purpose of the Study:

• To review the evolution of cancer chemotherapy.
• To highlight scientific progress in understanding tumor microenvironment and targeted therapy.
• To present approaches and evidence for developing novel cancer agents.

Main Methods:

• Literature review of historical and recent advancements in cancer chemotherapy.
• Analysis of key hypotheses in chemotherapy (log kill, Norton-Simon, Goldie-Coldman).
• Examination of molecular biology breakthroughs enabling targeted therapy development.

Main Results:

• Chemotherapy has transitioned from broad genotoxic agents to molecularly targeted therapies.
• Understanding of tumor microenvironment and carcinogenesis pathways has advanced significantly.
• Novel agents modulating dysregulated molecular pathways are emerging.

Conclusions:

• Modern cancer chemotherapy benefits from decades of research into drug action and tumor biology.
• Targeted therapies represent a paradigm shift, offering more precise cancer treatment strategies.
• Continued research in molecular biology is crucial for developing next-generation cancer agents.